Tecentriq (atezolizumab) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

439 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
ECLIPSE, NCT03395899 / 2016-004424-38: Pre-operative Immunotherapy Combination Strategies in Breast Cancer

Completed
2
71
Europe
Atezolizumab, Cobimetinib, Ipatasertib, Bevacizumab
Queen Mary University of London, Kliniken Essen-Mitte, MedSIR, Asan Medical Center, Hoffmann-La Roche
Breast Cancer, Estrogen Receptor-positive Breast Cancer
08/23
08/23
iReP, NCT04865250: Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

Recruiting
2
20
Europe
Atezolizumab 1200 mg abs day 1 q22 (iv), Carboplatin AUC5 day 1 q22 (iv), Nab-Paclitaxel 100 mg/m2 day 1,8,15 q22
University Hospital Heidelberg, Dietmar Hopp Stiftung
NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB
11/24
12/26
SOGUG-AUREA, NCT04602078: Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Completed
2
66
Europe
Atezolizumab 1200 mg/m2, Tecentriq, Gemcitabine 1000 mg/m2, Cisplatin 70 mg/m2
Spanish Oncology Genito-Urinary Group, Roche Pharma AG
Locally Advanced or Metastatic Urothelial Carcinoma
02/24
02/24
SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting
2
99
Europe
MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil
GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG
Anal Cancer
02/23
12/24
2022-002265-15: A Study of RO7247669 Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer who are Ineligible for Platinum-Containing Chemotherapy

Ongoing
2
240
Europe
PD1-LAG3, tiragolumab, RO7247669/F01-01, RO5541267/F03-01, RO7092284/F03-01, Solution for infusion, Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Tecentriq®
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer, Urothelial Bladder Cancer is common type of cancer that has spread outside of the bladder to other parts of the body, this causes back pain, painful urination, frequent urination, and blood in urine., Diseases [C] - Cancer [C04]
 
 
NCT05001347: A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Completed
2
25
US
TJ004309
I-Mab Biopharma US Limited
Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer, Triple Negative Breast Cancer, Ovarian Carcinoma
02/23
02/23
CUPISCO, NCT03498521 / 2017-003040-20: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Active, not recruiting
2
528
Europe, Japan, RoW
Alectinib, Vismodegib, Ipatasertib, Olaparib, Erlotinib, Bevacizumab, Vemurafenib, Cobimetinib, Trastuzumab Subcutaneous (SC), Pertuzumab, Atezolizumab, Carboplatin, Paclitaxel, Cisplatin, Gemcitabine, Entrectinib, Ivosidenib, Pemigatinib
Hoffmann-La Roche, Foundation Medicine, Inc.
Cancer of Unknown Primary Site
02/23
06/24
NCT04510584: Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Withdrawn
2
20
Canada
Atezolizumab, TECENTRIQ, Bevacizumab, AVASTIN
University Health Network, Toronto
Ovarian Endometrioid Tumor, Fallopian Tube Cancer, Primary Peritoneal Cancer, TP53 Mutation
02/23
02/23
NCT03262454: Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC

Recruiting
2
35
RoW
Atezolizumab, Tecentriq
National Cancer Center, Korea, Roche Korea co.,Ltd.
Small Cell Lung Cancer Recurrent
02/23
07/24
PRINCEPS, NCT02994576: Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer

Completed
2
60
Europe
Atezolizumab
Gustave Roussy, Cancer Campus, Grand Paris
Nonsmall Cell Lung Cancer
03/23
03/23
BACCI, NCT02873195: Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Active, not recruiting
2
133
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Capecitabine, Ro 09-1978/000, Xeloda, Laboratory Biomarker Analysis, Placebo, placebo therapy, PLCB, sham therapy
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
03/23
07/24
2022-003708-33: A PHASE II STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RECURRENCE AND HIGH TUMOR MUTATIONAL BURDEN OR MICROSATELLITE INSTABILITY. ESTUDIO FASE II DE ATEZOLIZUMAB O ATEZOLIZUMAB EN COMBINACIÓN CON TIRAGOLUMAB COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON TUMORES SÓLIDOS RESECABLES CON RIESGO DE RECURRENCIA INTERMEDIO-ALTO Y ALTA CARGA MUTACIONAL TUMORAL O INESTABILIDAD DE MICROSATÉLITES

Not yet recruiting
2
40
Europe
Atezolizumab, tiragolumab, RO5541267, RO7092284/F03-01, Concentrate for solution for infusion, Tecentriq
Roche Farma S.A.U., Roche Farma S.A.U.
Solid tumors Tumores sólidos, Solid tumors are abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancerous), or malignant (cancerous) Los tumores sólidos son masas anormales de tejido que generalmente no contienen quistes o áreas líquidas. Los tumores sólidos pueden ser benignos (no cancerosos) o malignos (cancerosos), Diseases [C] - Cancer [C04]
 
 
EndoBARR, NCT03694262: The Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Completed
2
30
US
Rucaparib, Rubraca, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Medical College of Wisconsin, Genentech, Inc., Clovis Oncology, Inc.
Endometrial Cancer, Uterine Carcinosarcoma
03/23
04/23
NCI-2017-01387, NCT02451423: Neoadjuvant Atezolizumab in Localized Bladder Cancer

Completed
2
23
US
Atezolizumab, MPDL3280A
Lawrence Fong, Genentech, Inc., The Bladder Cancer Advocacy Network, Conquer Cancer Foundation, National Cancer Institute (NCI), The V Foundation
Carcinoma, Transitional Cell
03/23
03/23
NCT05886257: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Withdrawn
2
RoW
Candonilimab, Bevacizumab
Shi Ming
Hepatocellular Carcinoma
03/23
03/23
ALICE, NCT03164993: Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

Completed
2
68
Europe
Atezolizumab, Tecentriq, Pegylated liposomal doxorubicin, Cyclophosphamide, Placebo
Oslo University Hospital, Hoffmann-La Roche, Norwegian Cancer Society, St. Olavs Hospital, Helse Stavanger HF, Rigshospitalet, Denmark, Vejle Hospital, NanoString Technologies, Inc., Technical University of Denmark, Karolinska Institutet
Cancer, Breast, Triple Negative Breast Cancer
04/23
09/23
2016-003570-40: ALICE: A randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.

Not yet recruiting
2
75
Europe
Atezolizumab, Caelyx, Sendoxan, MPDL3280A-RO5541267-F-03, Solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Tablet, Tecentriq, Caelyx, Sendoxan
Oslo University Hospital (OUS), Roche
Triple-negative breast cancer patients With matasteses, Metastatic triple-negative breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT04661150: A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Active, not recruiting
2
41
RoW
Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Capecitabine, Oxaliplatin
Hoffmann-La Roche
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/23
08/26
NCT02091141: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Checkmark ASCO 2016
Jun 2016 - Jun 2016: ASCO 2016
Checkmark ASCO-GI 2016
Jan 2016 - Jan 2016: ASCO-GI 2016
Completed
2
673
US
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Erlotinib, Tarceva, Vemurafenib, Zelboraf, Cobimetinib, Cotellic, Vismodegib, Erivedge, Alectinib, Alecensa, Atezolizumab, Tecentriq
Genentech, Inc.
Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
05/23
05/23
SWOG S1605, NCT02844816: Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Checkmark From P2 trial for NMIBC
May 2020 - Jun 2020: From P2 trial for NMIBC
Active, not recruiting
2
172
Canada, US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq
National Cancer Institute (NCI), Canadian Cancer Trials Group
Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
06/23
09/24
CeLEBrATE, NCT04730999 / 2019-003798-25: Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

Active, not recruiting
2
52
Europe
Etoposide, Carboplatin, Bevacizumab, Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma, Italy, YGHEA, CRO Division of Ecol Studio spa, Dr. Luca Boni U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino - IST NORD CBA
Small Cell Lung Cancer
06/23
10/24
ATRACTIB, NCT04408118 / 2019-001503-20: First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Completed
2
100
Europe
Atezolizumab, Paclitaxel, Bevacizumab, Avastin
MedSIR, Hoffmann-La Roche
Metastatic Breast Cancer, Advanced Breast Cancer, Triple Negative Breast Cancer
12/23
12/23
AZTEC, NCT03464942: Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

Completed
2
54
RoW
SABR, Atezolizumab
Peter MacCallum Cancer Centre, Australia, Trans Tasman Radiation Oncology Group
Breast Cancer
06/23
06/23
NCT02478099 / 2015-000907-19: MPDL3280A-treatment-IST-UMCG

Active, not recruiting
2
81
Europe
MPDL3280A
University Medical Center Groningen
Locally Advanced or Metastatic Solid Tumors
09/23
07/24
NCT02883062: Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Active, not recruiting
2
67
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
12/19
01/25
ABACUS-2, NCT04624399 / 2019-004628-39: Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

Recruiting
2
58
Europe
Atezolizumab, MPDL3280A
Queen Mary University of London, Hoffmann-La Roche
Urogenital Cancer
07/23
12/24
NCT04308785: A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Terminated
2
24
RoW
Atezolizumab, Tecentriq, Tiragolumab, Placebo
Hoffmann-La Roche
Carcinoma, Small Cell Lung
07/23
07/23
neoMono, NCT04770272 / 2020-001651-40: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Active, not recruiting
2
416
Europe
Atezolizumab 840 MG in 14 ML Injection, Tecentriq, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Biopsy Arm A, Biopsy Arm B, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, Phaon Scientific GmbH, University Hospital, Essen, University Hospital Erlangen
Triple-negative Breast Cancer
07/23
08/24
NCT04405349: Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Completed
2
52
Europe, RoW
VB10.16, Atezolizumab, Tecentriq
Nykode Therapeutics ASA, Roche Pharma AG, Vaccibody AS
Cervical Cancer, Cervix Cancer
11/23
11/23
NCT03474094: Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

Recruiting
2
69
Europe
Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery, 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.
Centre Leon Berard, Roche Pharma AG
Sarcoma,Soft Tissue
08/23
08/24
NCT06390059: EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
2
76
Europe
Tumor Treating Fields, NovoTTF-200T, Atezolizumab, Tecentriq (Brand name), Gemcitabine, Gemzar, nab-paclitaxel, Abraxane
NovoCure GmbH
Metastatic Pancreatic Ductal Adenocarcinoma
08/26
08/26
TARZAN, NCT04017455: Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab

Recruiting
2
38
Europe
Atezolizumab, MPDL3280A, Bevacizumab, HCA 185 ,Avastin
The Netherlands Cancer Institute, Hoffmann-La Roche
Rectal Cancer
08/23
08/24
NCT03526432: Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Checkmark Data from P2 trial in combination with Avastin in recurrent endometrial cancer at IGCS 2022
Oct 2022 - Oct 2022: Data from P2 trial in combination with Avastin in recurrent endometrial cancer at IGCS 2022
Active, not recruiting
2
110
US
Bevacizumab, Atezolizumab
University of Oklahoma, Genentech, Inc.
Endometrial Cancer
08/24
05/25
MARIO-3, NCT03961698: Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Checkmark Early data from MARIO-3 trial in combination with IPI-549 for 1L RCC
Dec 2021 - Dec 2021: Early data from MARIO-3 trial in combination with IPI-549 for 1L RCC
Hourglass Jun 2021 - Jun 2021 : Additional data from MARIO-3 trial in combination with Abraxane and IPI-549 for 1L TNBC at ASCO 2021
Checkmark From MARIO-3 trial in combination with IPI-549 + Abraxane for 1L TNBC
Dec 2020 - Dec 2020: From MARIO-3 trial in combination with IPI-549 + Abraxane for 1L TNBC
Active, not recruiting
2
91
US
IPI-549 (eganelisib), Atezolizumab, Tecentriq, nab-paclitaxel, Abraxane, Bevacizumab, Avastin
Infinity Pharmaceuticals, Inc., Roche Pharma AG
Breast Cancer, Renal Cell Carcinoma
08/23
08/23
SKYSCRAPER-09, NCT04665843 / 2020-002852-19: A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
123
Europe, US, RoW
Atezolizumab, Tecentriq; RO5541267, Tiragolumab, RO7092284, Placebo
Hoffmann-La Roche
Squamous Cell Carcinoma of Head and Neck
09/23
10/24
NCT03513952: Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Active, not recruiting
2
47
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Glycosylated Recombinant Human Interleukin-7, CYT-107, CYT107, Glycosylated rhIL-7, INTERLEUKIN-7 HUMAN RECOMBINANT, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography and Computed Tomography Scan, PET-CT Scan, PET/CT SCAN, Positron Emission Tomography/Computed Tomography
National Cancer Institute (NCI)
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
09/23
10/24
PORTAL, NCT05625893: Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Recruiting
2
63
RoW
PBT and atezolizumab/bevacizumab
Samsung Medical Center
Hepatocellular Carcinoma, Portal Vein Thrombosis
09/23
12/25
NCT03693014: A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Recruiting
2
60
US
Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
Memorial Sloan Kettering Cancer Center
Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
10/25
10/25
IMMUNOGAST, NCT04739202: Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma

Recruiting
2
60
Europe
Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab
Hospices Civils de Lyon
Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma
10/23
10/23
NCT06254911: Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Recruiting
2
20
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Transoral Surgery with cervical lymphadenctomy (neck dissection), Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging
Emory University, National Cancer Institute (NCI), Genentech, Inc.
Oropharynx Cancer, Stage I
08/25
08/26
NCT04933227: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Terminated
2
29
RoW
Atezolizumab, Tecentriq, Tiragolumab, Oxaliplatin, Capecitabine
Hoffmann-La Roche
Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
11/23
11/23
FLUORO, NCT04962126: Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Active, not recruiting
2
15
RoW
Obinutuzumab 25 MG/1 ML Intravenous Solution, Gazyva, Atezolizumab 1200 MG/40mL Intravenous Solution, Tecentriq, 4 Gy in 2 fractions
Olivia Newton-John Cancer Research Institute, Roche Products Pty Limited, Austin Health, Ballarat Health Services
Follicular Lymphoma
04/23
07/25
MiST, NCT03654833: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24
NCT06138769: Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

Recruiting
2
50
RoW
Lenvatinib
Asan Medical Center, Eisai Inc., Chonnam National University Hospital, Seoul National University, Gangneung Asan Hospital, Ulsan University Hospital, Chosun University Hospital, Dong-A University Hospital, Bundang CHA Hospital, Seoul National University Bundang Hospital, Yonsei University, Hanyang University Seoul Hospital, Chungnam National University Hospital, Saint Vincent's Hospital, Korea, Gyeongsang National University Hospital, Ewha Womans University, Chungbuk National University Hospital, Severance Hospital, Gachon University Gil Medical Center, The Catholic University of Korea, Bucheon St. Mary's Hospital
Hepatocellular Carcinoma
11/26
11/27
IMscin002, NCT05171777: A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Active, not recruiting
2
176
Europe, Canada, US, RoW
Atezolizumab, Tecentriq
Hoffmann-La Roche
Non-small Cell Lung Cancer
11/23
09/24
ProtonAB, NCT06133062: Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Recruiting
2
45
RoW
Atezolizumab, Bevacizumab, Proton radiotherapy
Chang Gung Memorial Hospital
Hepatocellular Carcinoma Non-resectable
09/28
09/30
2019-002328-33: A Phase 2 study for the Combination of VB10.16 and Atezolizumab in Patients with Advanced Cervical Cancer Essai multicentrique de phase 2a sur l’association du VB10.16 et de l’Atezolizumab chez les patientes atteintes d’un cancer du col de l’utérus , avancé ou récidivant

Not yet recruiting
2
50
Europe, RoW
VB10.16, Atezolizumab, VB10.16, Atezolizumab, Solution for injection, Concentrate for solution for infusion, Tecentriq
Nykode Therapeutics ASA, NYKODE THERAPEUTICS ASA, Nykode Therapeutics A.S., VACCIBODY A.S., Nykode Therapetics ASA, NYKODE THERAPEUTICS ASA, Nykode Therapeutics ASA, Nykode Therapeutics A.S., VACCIBODY AS
Advanced or recurrent non-resectable HPV16-positive cervical cancer, who failed or are not eligible for current standard of care, Advanced cervical cancer, Diseases [C] - Cancer [C04]
 
 
NCT03125928: Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Active, not recruiting
2
16
US
Atezolizumab, Paclitaxel, Trastuzumab, Pertuzumab
Fox Chase Cancer Center, Genentech, Inc.
HER2-positive Breast Cancer
06/24
12/24
ACHILES, NCT03540420 / 2017-004572-62: Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Active, not recruiting
2
212
Europe
Atezolizumab, anti-PDL1, Tecentriq
Norwegian University of Science and Technology, University Hospital of North Norway, Alesund Hospital, Vestre Viken Hospital Trust, University Hospital, Akershus, Helse Nord-Trøndelag HF, Helse Stavanger HF, Haukeland University Hospital, Sorlandet Hospital HF, Ullevaal University Hospital, Molde Hospital, Helse Fonna, Nordlandssykehuset HF, Volda Hospital, Kristiansund Hospital, Sahlgrenska University Hospital, Sweden, Skane University Hospital, Karolinska University Hospital, Ôrebro University Hospital, Gävle Hospital, University Hospital, Linkoeping, Odense University Hospital, Aalborg University Hospital, Rigshospitalet, Denmark, National Cancer Institute, Lithuania, Kantonsspital Winterthur KSW, University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, Kantonsspital Graubünden, Freiburger Spital, Klinik Hirslanden, Zurich, Kantonsspital Olten, Spital STS AG, Ente Ospedaliero Cantonale, Bellinzona, Cantonal Hospital of St. Gallen, St. Olavs Hospital, Oslo University Hospital, Rijnstate Hospital, Isala, Zuyderland Medisch Centrum, The Netherlands Cancer Institute, St. Antonius Hospital, Amphia Hospital, Medisch Spectrum Twente, Erasmus Medical Center
Small-cell Lung Cancer
04/24
04/27
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Active, not recruiting
2
80
US
Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab
SCRI Development Innovations, LLC, Genentech, Inc.
Non-Small Cell Lung Cancer, Solid Tumor
07/24
07/24
SPACE, NCT04221529: Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Active, not recruiting
2
70
Europe
Atezolizumab
AIO-Studien-gGmbH, Hoffmann-La Roche
SCLC, Extensive Stage
04/24
10/24
CABATEN, NCT04400474: Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The Study

Active, not recruiting
2
93
Europe
Cabozantinib 40 mg, Atezolizumab 1200 mg
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, Roche Pharma AG
Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma
12/23
03/24
NEO-TIM, NCT04722575 / 2018-004841-17: Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting
2
95
Europe
Cobimetinib 20 MG Oral Tablet, Cotellic, Vemurafenib 240 Mg Oral Capsule, Zelboraf, Atezolizumab 1200 MG in 20 ML Injection, Tecentriq
Fondazione Melanoma Onlus, Clinical Research Technology S.r.l.
Melanoma
12/23
06/27
DYNAMIC, NCT04954339: DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

Recruiting
2
45
RoW
Aatezolizumab plus Bevacizumab, Ticentriq plus Avastin
Tae Won Kim
Hepatocellular Carcinoma
12/23
12/25
SKYROCKET, NCT05034055: Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer

Not yet recruiting
2
45
RoW
atezolizumab / tiragolumab
Yonsei University
Non-small Cell Lung Cancer
12/23
12/23
NCT05396937: Efficacy and Safety of T+A+RAD in HCC

Recruiting
2
42
RoW
Multifocal Stereotactic Radiotherapy, Atezolizumab Injection [Tecentriq], Bevacizumab
Fudan University, Roche Pharma AG
Hepatocellular Carcinoma
12/23
12/23
NCT04135690: HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Recruiting
2
60
RoW
Hepatic arterial infusion chemotherapy, Toripalimab, Sorafenib, systemic treatment
Sun Yat-sen University
Hepatocellular Carcinoma
12/23
12/23
ATREZZO, NCT04759248 / 2020-000245-13: Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Recruiting
2
55
Europe
Atezolizumab + Trastuzumab + Vinorelbine
SOLTI Breast Cancer Research Group, Roche Pharma AG
Breast Cancer
12/24
01/25
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
ABC-lung, NCT04245085 / 2019-001687-30: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Active, not recruiting
2
95
Europe, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Carboplatin, Paclitaxel, Pemetrexed, Alimta
ETOP IBCSG Partners Foundation, Roche Pharma AG
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
12/24
12/24
NCT04321330: A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Completed
2
34
RoW
Atezolizumab, MPDL3280A; RO5541267; Tecentriq
Hoffmann-La Roche
Carcinoma, Thymic
07/23
06/24
ChiCTR2000039310: Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China

Recruiting
2
208
 
Almonertinib, 110mg, qd ;Dacomitinib, 450mg, qd ;Alectinib, 600mg, bid ;Crizotinib, 250mg, bid ;Zelboraf, 960mg, bid ;Niraparib,200-300mg,qd ;Pyrotinib, 400mg, qd ;Imatinib, 400mg, bid ;Palbociclib, 125mg,*21d, q28d ;Sintilimab, 200mg, q21d ;Atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d
National Cancer Center/National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital of Chinese Academy of Medical Sciences, self-raised
Rare Tumors
 
 
LUN 17-139, NCT03786692: Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

Recruiting
2
117
US
Arm A, Arm B
Fox Chase Cancer Center, National Comprehensive Cancer Network
Non-Small Cell Carcinoma of Lung, TNM Stage 4
01/25
01/27
BTCRC-LUN19-396, NCT04367311: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Recruiting
2
100
US
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Nasser Hanna, Genentech, Inc.
Lung Cancer, NSCLC
06/24
01/25
AURORA, NCT05038657: Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

Recruiting
2
36
Europe
Atezolizumab, Treatment
University Hospital Southampton NHS Foundation Trust, Cancer Research UK, Roche Pharma AG
Squamous Cell Carcinoma, Urinary Tract Cancer
01/24
01/25
STRATUM, NCT05377034: Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

Recruiting
2
176
RoW
SIRT-Y90 with Atezolizumab + Bevacizumab, SIRT-Y90 with Placebo (IV)
National Cancer Centre, Singapore, Hoffmann-La Roche, Sirtex Medical, Singapore Clinical Research Institute
Locally Advanced Hepatocellular Carcinoma
04/25
10/26
NCT05760599: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Recruiting
2
30
RoW
Candonilimab, Bevacizumab
Shi Ming
Hepatocellular Carcinoma
01/24
07/24
HOVON 151, NCT03463057 / 2017-002605-35: The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

Active, not recruiting
2
109
Europe
Atezolizumab, Tecentriq, L01XC
Stichting Hemato-Oncologie voor Volwassenen Nederland
NHL, DLBCL
01/24
01/27
TELMA, NCT03836066 / 2018-004654-17: Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Checkmark Results from TELMA study for stage IIIB-IV, non-squamous TMB-high 1L NSCLC
Dec 2022 - Dec 2022: Results from TELMA study for stage IIIB-IV, non-squamous TMB-high 1L NSCLC
Active, not recruiting
2
41
Europe
Atezolizumab-Bevacizumab, Tecentriq-Avastin
Fundación GECP
Non Small Cell Lung Cancer
11/24
01/25
DETERRED, NCT02525757: MPDL3280A With Chemoradiation for Lung Cancer

Active, not recruiting
2
52
US
MPDL3280A, Carboplatin, Paraplatin, Paclitaxel, Taxol, Radiation Therapy, XRT
M.D. Anderson Cancer Center, Genentech, Inc.
Lung Cancer, Non-Small Cell Lung Cancer
01/26
01/26
NCI-2018-01399, NCT03108131: Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Completed
2
49
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant Neoplasm, Metastatic Skin Squamous Cell Carcinoma, Metastatic Small Intestinal Adenocarcinoma, Rare Neoplastic Syndrome, Refractory Malignant Neoplasm, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Unresectable Malignant Neoplasm
04/24
04/24
NCT03237780: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Active, not recruiting
2
72
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog
National Cancer Institute (NCI)
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
06/25
06/25
NCT03756298: Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Active, not recruiting
2
284
RoW
Atezolizumab, Arm A, Capecitabine, Arm B
National Cancer Center, Korea
Triple Negative Breast Cancer
01/24
01/27
NCT05199285: A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Recruiting
2
40
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Academic and Community Cancer Research United, National Cancer Institute (NCI)
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
01/24
01/27
NCT04923776: Liver Directed RT + Chemo-immunotherapy for ES-SCLC

Recruiting
2
18
US
Carboplatin, Paraplatin, Etoposide, Vepesid, Atezolizumab, Tecentriq, Stereotactic Body Radiation Therapy (SBRT)
Brian Henick, MD
Small-cell Lung Cancer
02/24
02/25
BIS-Program, NCT05180006: Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Recruiting
2
185
Europe
Atezolizumab Injection, Bevacizumab, Pertuzumab, Trastuzumab
Gustave Roussy, Cancer Campus, Grand Paris, Hoffmann-La Roche
Breast Cancer
02/25
02/26
BEACON, NCT03363867: - ABC in Recurrent Platinum Resistant HGSOC

Active, not recruiting
2
30
RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Cobimetinib, Cotellic
Peter MacCallum Cancer Centre, Australia
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
02/24
06/25
NCT05751343: TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Recruiting
2
55
RoW
TACE-HACI, plus atezolizumab-bevacizumab
Sun Yat-sen University
Hepatocellular Carcinoma
02/24
02/25
NCT05009069: A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Active, not recruiting
2
58
RoW
Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab
Hoffmann-La Roche
Rectal Neoplasms, Rectal Cancer
11/23
10/26
ImmunoCobiVem, NCT02902029 / 2015-005097-37: Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Completed
2
186
Europe, RoW
Vemurafenib, Cobimetinib, Atezolizumab
University Hospital, Essen
Malignant Melanoma
03/24
03/24
NCT03093922: A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Active, not recruiting
2
32
US
Atezolizumab, Gemcitabine, Cisplatin
Memorial Sloan Kettering Cancer Center, Ohio State University, University of Chicago, Genentech, Inc., Targos
Urothelial Carcinoma, Locally Advanced, Unresectable
03/25
03/25
ATHENA, NCT03818061: Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

Active, not recruiting
2
33
Europe
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Centre Leon Berard
Head and Neck Neoplasms
03/24
03/24
NCT04820179: Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

Recruiting
2
29
US
Cabozantinib + Atezolizumab
University of Arizona
Pancreatic Cancer, Metastatic Pancreatic Cancer
03/25
03/25
NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Active, not recruiting
2
134
US, RoW
SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo
Coherus Biosciences, Inc.
Hepatocellular Carcinoma
05/25
05/26
NAUTIKA1, NCT04302025: A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

Recruiting
2
125
US
Alectinib, Entrectinib, Vemurafenib (Enrollment closed), Cobimetinib (Enrollment closed), Pralsetinib (Enrollment closed), Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Genentech, Inc., Blueprint Medicines Corporation
Non-small Cell Lung Cancer
12/25
03/29
SKYLINE, NCT06175390: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Recruiting
2
160
Europe
68Ga-FAPI-46 PET/CT, Tumor samples analysis, Blood samples analysis: Circulating Tumor DNA
Institut Curie, Hoffmann-La Roche
Triple Negative Breast Cancer
08/26
02/29
PhotonAB, NCT06339424: Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma

Not yet recruiting
2
45
RoW
Atezolizumab, Bevacizumab, Photon radiotherapy
Chang Gung Memorial Hospital
Hepatocellular Carcinoma
03/29
03/31
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
IMMORTAL, NCT04936230: Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Recruiting
2
144
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
National Cancer Institute (NCI)
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
04/25
04/25
ABATE, NCT04289779: Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer

Recruiting
2
46
US
Cabozantinib, cabometyx, Atezolizumab, Tecentriq, Cystectomy
Deepak Kilari, Exelixis, Genentech, Inc., Medical College of Wisconsin
Bladder Cancer
05/24
05/25
NCT05404048 / 2021-005192-39: PD-L1 PET-imaging During CAR T-cell Therapy

Recruiting
2
20
Europe
89Zr-atezolizumab PET-imaging
University Medical Center Groningen
Large B-cell Lymphoma
05/24
05/25
NCT06429696: PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

Not yet recruiting
2
40
NA
PD-L1 inhibitor combined with apatinib
Nanfang Hospital, Southern Medical University
Small Cell Lung Cancer Extensive Stage
04/26
04/26
IMMUNO-TH, NCT06254248: Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2
50
NA
Systemic therapy
Assistance Publique - Hôpitaux de Paris
Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment
05/28
12/28
NCT04322643: Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Completed
2
4
US
Pembrolizumab, KEYTRUDA, Atezolizumab, TECENTRIQ, Durvalumab, IMFINZI, Nivolumab, OPDIVO, Avelumab, BAVENCIO
Case Comprehensive Cancer Center
Urothelial Carcinoma
08/22
04/23
NCT04710498: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Active, not recruiting
2
20
US
Atezolizumab, RO5541267
Stanford University, Genentech, Inc.
Cutaneous Squamous Cell Carcinoma
02/24
11/24
PIONEER, NCT04939480: Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

Completed
2
20
Europe
Atezolizumab
University Hospital, Essen
Squamous Cell Carcinoma of Head and Neck
03/24
03/24
NCT05312671: Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Recruiting
2
63
US
Atezolizumab, Tecentriq, Carboplatin, CBDCA, Paraplatin, JM-8, NSC-241240, Cisplatin, Cis-Diaminedichloroplatinum, CDDP, Etoposide, VP-16, VePesid, VP-16-213, EPEG, epipodophyllotoxin, NSC # 141540, Cystectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genentech, Inc.
Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
06/25
06/27
NCT05429866: Immunological Variables Associated to ICI Toxicity in Cancer Patients

Recruiting
2
441
Europe
Checkpoint Blockade, Immune, Ipililumab, Nivolumab, Pembrozilumab, atezolizumab, avelumab, durvalumab, Cemiplimab
Jules Bordet Institute
Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Mesothelioma, Malignant, Bladder Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, MSI-H Colorectal Cancer
06/24
12/24
 

Download Options